Adverse event recording failed to reflect potential harms: a review of trial protocols of behavioral, lifestyle and psychological therapy interventions.


Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
08 2021
Historique:
received: 21 10 2020
revised: 07 02 2021
accepted: 01 03 2021
pubmed: 9 3 2021
medline: 16 10 2021
entrez: 8 3 2021
Statut: ppublish

Résumé

To explore how potential harms are assessed in trials of behavioral, lifestyle and psychological therapy interventions. This study was a review of protocols from the National Institute of Health Research Health Technology Assessment and Public Health Research programmes. Protocols were included if the study was a randomized controlled trial and the intervention intended to change lifestyle or behavior to improve health or improve psychological outcomes. 95 of 151 protocols planned to record adverse events (AEs). Definitions of AEs were often not given and varied widely. Serious AEs were mostly defined using standards originally devised for pharmacological trials. Twenty-two protocols listed expected AEs. Few protocols described assessment of causation between AEs and intervention. Examples of useful AE recording practice were identified. Monitoring and recording AEs in behavioral intervention trials was variable and frequently based on reporting guidelines for pharmacological trials. This may mean potential harms are being missed. Future trials should consider: 1) Potential harms posed by the intervention 2) How to define serious AEs 3) What are expected AEs. Further research to achieve consensus on AE recording is required, including identification of core adverse outcomes in clinical areas or caused by interventions.

Identifiants

pubmed: 33684508
pii: S0895-4356(21)00074-3
doi: 10.1016/j.jclinepi.2021.03.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-76

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Diana Papaioannou (D)

Sheffield Clinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom. Electronic address: d.papaioannou@sheffield.ac.uk.

Cindy Cooper (C)

Sheffield Clinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.

Cara Mooney (C)

Sheffield Clinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.

Rachel Glover (R)

Sheffield Clinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.

Elizabeth Coates (E)

Sheffield Clinical Trials Research Unit, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH